Clinical trials: Primary Progressive Multiple Sclerosis
Multiple Sclerosis, Pathologic Processes
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
- Conditions
- Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases
- Trial name
- NCT03562975
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of South Florida
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with PPMS…
- Trial name
- GAVOTTE (NCT04548999)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 147 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Hoffmann-La Roche
Primary Progressive Multiple Sclerosis
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.
- Trial name
- ARPEGGIO (NCT02284568)
- Testing
- Laquinimod
- Where
- 99 sites in United States, Canada and 8 more
- Volunteers
- 374 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS
The purpose of this study is to examine the effect of treatment with fampridine in patients with secondary progressive MS (SPMS) or primary progressive MS (PPMS) with upper limb dysfunction (as defined by a 9-HPT time of between…
- Trial name
- NCT02208050
- Testing
- Fampridine
- Where
- 2 sites in Ireland
- Volunteers
- 64 people
- Sponsor
- University College Dublin
Primary Progressive Multiple Sclerosis
This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS.
- Trial name
- INFORMS (NCT00731692)
- Testing
- FTY720
- Where
- 157 sites in United States, Australia and 16 more
- Volunteers
- 970 people
- Sponsor
- Novartis Pharmaceuticals
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
ACTH in Progressive Forms of MS
This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar gel) administered as a pulsed regimen consisting…
- Conditions
- Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT01950234
- Testing
- ACTH
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Minnesota
Multiple Sclerosis
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for…
- Trial name
- NCT01970410
- Testing
- teriflunomide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Providence Health & Services
Primary Progressive Multiple Sclerosis
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Background: Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system that progressively weakens and destroys the pathways of the nervous system.
- Trial name
- IPPoMS (NCT00950248)
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Migraine, Headache
RELAXaHEAD for Headache Patients (Phase II)
The goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (PMR) for the treatment of migraine and sleep.
- Conditions
- Migraine, Headache, Multiple Sclerosis, Insomnia
- Trial name
- NCT05466682
- Testing
- Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- NYU Langone Health
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Idebenone for Primary Progressive Multiple Sclerosis
Background: The Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) trial tested a new drug for multiple sclerosis. In the IPPoMS trial, participants took either idebenone or placebo.
- Trial name
- NCT01854359
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
This study will evaluate if giving insulin that is administered in the nostrils (intranasal) is safe and tolerable for people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02988401
- Testing
- Insulin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Multiple Sclerosis
A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
This study is an open-label, non-randomized study to evaluate rate and severity of infusion-related reactions (IRRs) of ocrelizumab infused over a shorter time period than the approved administration rate in participants with…
- Trial name
- NCT03606460
- Testing
- Ocrelizumab Dose 1, Ocrelizumab Dose 2 and Dose 3
- Where
- 5 sites in United States
- Volunteers
- 141 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course.
- Trial name
- O'HAND (NCT04035005)
- Testing
- Ocrelizumab
- Where
- 155 sites in United States, Australia and 21 more
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of…
- Trial name
- Ocarina II (NCT05232825)
- Testing
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV
- Where
- 37 sites in United States, Brazil and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS.
- Trial name
- NCT02688985
- Testing
- Ocrelizumab, Lumbar Puncture, Methyloprednisolone
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 131 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Primary Progressive
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
This randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis.
- Trial name
- NCT01194570
- Testing
- Ocrelizumab
- Where
- 184 sites in United States, Australia and 27 more
- Volunteers
- 735 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS.
- Trial name
- OLYMPUS (NCT00087529)
- Testing
- rituximab
- Volunteers
- 439 people
- Sponsor
- Genentech, Inc.